GLG News by Nursing Home & Skilled Nursing Facility Experts

Congress is looking at making cuts to Medicare especially the privately administered Medicare Advantage plans. America's Health Insurance Plans (AHIP) the advocacy group is concerned solely with preserving the healthy margins enjoyed by its members, while Congress is interested in reducing Medicare...

Primary care physicians, often overworked and underpaid for their efforts are seeing a new way to return to the traditional practice style of physcians many years ago, offering appointments lasting more than 6 minutes, and a host of personal touches.   By charging a premium for this service...

Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry. We know these...

Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry.   ...

Siemens, a German company, known for medical diagnostic equipment such as imaging devices is acquiring Dade-Behring to expand its portfolio into the clinical lab science diagnostic area. As predicted in a post I did on February 28, we will be seeing more "fully diagnostic" companies combining the...

Patients with hormone refractory prostate cancer have few options for treatment, and can be a challenge to manage.   Taxotere has shown an overall survival benefit in this patient population, however, when patients become refractory to this, there are no real viable options. Many companies...

Another example of the erosion of a physicians autonomy. While recent data has suggested some concerns with the use of ESA's in cancer patients, the risk of cardiovascular and thromboembolic events was associated with HgB>12. Certainly, in the past we were less cautios about the HgB. CMS has now...

Erbitux has been very successful in the colorectal cancer and head and neck trials.   The EGFR receptor is prevalent in many malignancies, and represents an obvious direction to expand the use of erbitux in other malignancies - ie lung cancer, esophagus, etc. As more indications for erbtitux...

Let's face it - the rural US is a relatively 'undesirable' (please don't get offended) location, with little access to a big city or collegiality with other physicians.   It also poses a challenge, as there are limited access to specialists.    I suspect it's not a dream job...

New small molecule inhibitor of androgen receptor - mechanism not completely known, but likely similar idea to other small molecule inhibitors in development for other receptors. Target population is hormone refractory prostate cancer, for which there is little viable therapy.   This is the...